Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2013

View Archived Issues

Inhibition of a kinase to prevent maladaptive changes during cardiac reperfusion

SUVN-911 demonstrates antidepressant activity in vivo

Phase III studies of clonidine gel for painful diabetic neuropathy to begin next year

Exelixis begins phase II trial of cabozantinib plus abiraterone/prednisone in prostate cancer

Sanofi Pasteur analyzes safety data for the CYD-TDV dengue vaccine

ARISE trial of sebelipase alfa reaches full enrollment

Celldex Therapeutics initiates study of glembatumumab vedotin for triple-negative breast cancer

AB Science initiates phase III study of masitinib for colorectal cancer

Medivation and Astellas begin phase III PROSPER study of enzalutamide

Lexicon Pharmaceuticals reports topline results from phase II LX-1033 study

FDA clears California Stem Cell's application for phase III cancer stem cell trial

Durata Therapeutics submits MAA for dalbavancin

Navidea Biopharmaceuticals begins phase III registration program for NAV-5001

Preliminary phase I results show safety and efficacy for PVSRIPO in patients with glioblastoma

Chinese researchers disclose new HDAC inhibitors for cancer

Tragara Pharmaceuticals begins trial of TG-02 in combination with carfilzomib

New CTLA-4 variants selected by MedImmune

Blaze Bioscience conducts financing round to support development of BLZ-100

The Albert Einstein College of Medicine patents new tuberculosis vaccine

Cancer Research Technology divulges new Chk1 inhibitors for cancer

Alphavirus-based vaccine encoding PSA tested in mouse model of prostate cancer

Novartis patents novel protein kinase inhibitors for cancer and viral infections

Telormedix raises funds to support phase II trial of TMX-101

Vivalis presents new agents for HCV infection

Teva and Takeda announce Japanese agreement for glatiramer acetate

Pharmacyclics describes novel BTK inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...